• Metal-Free Carbon Nanozymes for ALP Detection

  2026-08-12

  The reference study develops a metal-free carbon-dot nanozyme assay in which alkaline phosphatase hydrolysis of pyrophosphate releases a colorimetric signal. Its key contribution is mechanistic: Michaelis–Menten analysis shows that pyrophosphate inhibits the carbon dots at a site distinct from the catalytic center, supporting sensitive ALP measurement without metal-ion cofactors.

• ABT-888 (Veliparib) Workflow Guide

  2026-08-11

  Learn how to deploy ABT-888 (Veliparib) in DNA damage response assays, combination screens, and preclinical sensitization studies. The workflow connects PARP1/2 inhibition with practical readouts in colorectal cancer research and a biomarker-informed strategy inspired by recent ovarian cancer findings.

• Prochlorperazine in Applied Research

  2026-08-11

  Prochlorperazine is a dopamine D2 receptor antagonist that connects antiemetic pharmacology with practical melanoma, migration, and antiviral assay development. This guide translates its receptor profile, solubility constraints, concentration range, and safety signals into reproducible laboratory workflows.

• CB-5083: Practical p97 Inhibitor Workflows

  2026-08-10

  This scenario-based guide explains how CB-5083 (SKU B6032) can support reproducible p97 inhibition studies in viability, proliferation, and cytotoxicity workflows. It covers assay design, formulation, dose interpretation, and practical vendor-selection criteria using product data and a peer-reviewed reference.

• Aztreonam in CREC Resistance Assay Design

  2026-08-09

  Aztreonam offers a mechanistic lens for studying Gram-negative resistance beyond simple susceptibility testing. This article connects its monobactam pharmacology with plasmid transmission, carbapenemase surveillance, and assay design informed by a 2025 CREC study.

• 2'3'-cGAMP (Sodium Salt) Workflow Guide

  2026-08-08

  A practical guide to using 2'3'-cGAMP (sodium salt) in STING signaling, macrophage, and cancer immunotherapy assays. It connects direct pathway activation with formulation testing, phagocytosis measurements, and troubleshooting decisions that improve experimental interpretability.

• Dasatinib Monohydrate: A NET-Aware CML Assay Strategy

  2026-08-07

  Dasatinib Monohydrate and BMS-354825 enable a rigorous, multi-layer approach to chronic myeloid leukemia research. This article connects kinase selectivity, imatinib-resistant BCR-ABL inhibition, and NET biology while defining practical controls for interpretable assays.

• 2-Deoxy-D-glucose: Targeting Lactate-Driven Immune Resistanc

  2026-08-07

  Explore how 2-Deoxy-D-glucose disrupts lactate-mediated immune evasion in cancer by inhibiting glycolysis. This article offers advanced insights beyond standard workflows, revealing new strategies for reprogramming tumor immunometabolism.

• Bortezomib (PS-341) in Apoptosis Assays: Protocols and Insig

  2026-08-06

  Bortezomib (PS-341) empowers high-resolution apoptosis assays and mechanistic cancer studies by offering potent, selective 20S proteasome inhibition. This guide translates the latest cellular death pathway research into practical workflows, troubleshooting strategies, and advanced applications for oncology and proteostasis research.

• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP) in Can

  2026-08-06

  EZ Cap™ Human PTEN mRNA (ψUTP) is a next-generation in vitro transcribed mRNA solution designed for robust PTEN re-expression, immune evasion, and sustained pathway inhibition in advanced cancer models. This guide translates recent nanoparticle-mediated delivery breakthroughs into actionable protocols, troubleshooting insights, and comparative advantages for translational oncology research.

• DAPI (hydrochloride): Precision DNA Quantitation in Complex

  2026-08-05

  Explore how DAPI (hydrochloride) enables high-precision DNA quantitation and cell cycle analysis in advanced tumor models. This article provides a deep dive into its mechanistic nuances and protocol optimization, distinguishing it from prior content by focusing on quantitative applications and assay decision-making.

• FXR-KLF11 Axis: CDCA Protects Against CI-AKI via JAK2/STAT3

  2026-08-05

  The reference study demonstrates that Chenodeoxycholic Acid (CDCA), acting as a potent FXR agonist, confers renal protection against contrast-induced acute kidney injury (CI-AKI) by transcriptionally upregulating KLF11 and suppressing the JAK2/STAT3 pathway. These insights define the FXR-KLF11 signaling axis as a promising molecular target for developing prophylactic strategies in acute kidney injury research.

• β-Elemene Suppresses Adipogenesis via AMPK Pathway Activatio

  2026-08-04

  This study demonstrates that β-Elemene inhibits adipogenesis in 3T3-L1 preadipocytes by activating the AMPK pathway, reversing insulin resistance, and reducing lipid accumulation. These findings provide mechanistic insights and support β-Elemene's use as a research tool for metabolic disease modeling.

• PD0325901 in Translational Control: Beyond MEK Inhibition

  2026-08-04

  Explore how PD0325901, a potent MEK inhibitor, enables advanced studies of translational control and apoptosis induction in cancer cells. This article offers a unique perspective on integrating pathway inhibition with emerging insights into mRNA translation surveillance.

• Membrane-Binding Domain of CARMIL: Mechanisms in Actin Regul

  2026-08-03

  This study uncovers the multifaceted role of CARMIL's membrane-binding (MB) domain in actin filament regulation, revealing how it targets, activates, and releases capping protein (CP) at membrane sites. The findings clarify longstanding questions about the spatial and temporal control of actin assembly, with implications for understanding cellular morphodynamics and migration.

7950 records 3/530 page Previous Next 12345 下5页 Last page